OKT3 prophylaxis in liver transplant patients: a European and Australian multicenter, prospective controlled trial.
Höckerstedt
K
K
Fourth Department of Surgery, Helsinki University, Finland.
Ericzon
B G
BG
Bismuth
H
H
Chapuis
Y
Y
Farges
O
O
Faure
J L
JL
Galmarini
D
D
Houssin
D
D
Lynch
S V
SV
Miguet
J
J
D000328:Adult; D001379:Azathioprine / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000517:prevention & control*; D006085:Graft Survival; D006801:Humans; D016031:Liver Transplantation / Q000276:immunology*; D008297:Male; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D011446:Prospective Studies; D013256:Steroids / Q000627:therapeutic use; D016019:Survival Analysis; D013997:Time Factors
D016853:Muromonab-CD3; D013256:Steroids; D016572:Cyclosporine; D001379:Azathioprine